EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial

Alberto Biggi, Stephane Chauvie iD, Federico Fallanca, Luca Guerra, Fabrizio Bergesio, Massimo Menga, Andrea Bianchi, Michele Gregianin, Agostino Chiaravalloti, Orazio Schillaci, Chiara Pavoni, Caterina Patti und 9 weitere

Hematological Oncology · 2023

DOI: 10.1002/hon.3117 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Hematological Oncology, 2023. Verfasst von Alberto Biggi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Division, Santa Croce e Carle Hospital, Cuneo, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Associazione Italiana Contro le Leucemie-Linfomi e Mieloma, Fondazione Cassa di Risparmio di Cuneo, Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Lugano classification for response assessment in lymphoma recommends the use of the 5‐point‐scale Deauville Score (DS) to assess response evaluation of end‐of‐treatment FDG‐PET/CT (eotPET) in Hodgkin Lymphoma (HL); nevertheless, there is a paucity of data on its accuracy and reproducibility. We focus here on the cohort of advanced stage IIb‐IV HL patients enrolled in the HD0607 clinical trial (NCT identifier 00795613) that having had a negative interim PET performed 6 cycles of ABVD (Doxorubicin, Vinblastine, Vincristine and Dacarbazine) and then performed an eotPET. Negative patients were randomized to radiotherapy and no further treatment while positive patients were treated based on local policies. eotPET was re‐evaluated independently by two readers evaluated and progression free survival was analysed (PFS). eotPET of 254 patients were analysed. The median follow‐up was 43 months. The best receiver operator characteristics cut‐off values to distinguish positive and negative patients was 4. The area‐under‐the‐curve was 0.81 (95%CI, 0.70–0.91). Three‐years PFS was 0.95 (95% CI 0.90–0.97) in eotPET negative and 0.22 (95% CI 0.11–0.43) in eotPET positive. DS demonstrated a good reproducibility of positivity/negativity between the readers consensus and local site evaluation where the agreement occurred on 95.0% of patients. The present study demonstrates that eotPET is an accurate tool to predict treatment outcome in HL and confirms the appropriateness of the Lugano classification for eotPET evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseHumansPositron Emission Tomography Computed TomographyFluorodeoxyglucose F18DacarbazineVinblastineDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsReproducibility of ResultsBleomycinPositron-Emission TomographyTreatment Outcome

Stichwörter der Autor:innen

PETadvanced-stage hodgkin lymphomadeauvile criteriaend-of-treatment response assessment

Substanzen

Fluorodeoxyglucose F18DacarbazineVinblastineDoxorubicinBleomycin

Autor:innen und Institutionen

  • Nuclear Medicine Division, Santa Croce e Carle Hospital, Cuneo, Italy.
  • Medical Physics Division, Santa Croce e Carle Hospital, Cuneo, Italy.
  • Nuclear Medicine Division, IRCSS Ospedale San Raffaele, Milano, Italy.
  • Nuclear Medicine Division, Ospedale San Gerardo, Monza, Italy.
  • Nuclear Medicine Division, Ospedale Trieste, Trieste, Italy.
  • Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

ORCID-Profile: Stephane Chauvie, Livio Trentin

Förderung

  • Associazione Italiana Contro le Leucemie-Linfomi e Mieloma
  • Fondazione Cassa di Risparmio di Cuneo
  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Biggi, A., Chauvie, S., Fallanca, F., Guerra, L., Bergesio, F., Menga, M., Bianchi, A., Gregianin, M., Chiaravalloti, A., Schillaci, O., Pavoni, C., Patti, C., Picardi, M., Romano, A., Schiavotto, C., Sorasio, R., Viviani, S., La Nasa, G., Trentin, L., …, & Gallamini, A. (2023). Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial. Hematological Oncology. https://doi.org/10.1002/hon.3117

Vancouver

Biggi A, Chauvie S, Fallanca F, Guerra L, Bergesio F, Menga M, et al. Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial. Hematological Oncology. 2023. doi:10.1002/hon.3117

BibTeX
@article{Biggi2023,
  author = {Biggi, Alberto and Chauvie, Stephane and Fallanca, Federico and Guerra, Luca and Bergesio, Fabrizio and Menga, Massimo and Bianchi, Andrea and Gregianin, Michele and Chiaravalloti, Agostino and Schillaci, Orazio and Pavoni, Chiara and Patti, Caterina and Picardi, Marco and Romano, Alessandra and Schiavotto, Corrado and Sorasio, Roberto and Viviani, Simonetta and La Nasa, Giorgio and Trentin, Livio and Rambaldi, Alessandro and Gallamini, Andrea},
  title = {Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial},
  journal = {Hematological Oncology},
  year = {2023},
  doi = {10.1002/hon.3117}
}
Kostenlos starten →